Contributions
Abstract: EP1688
Type: ePoster
Abstract Category: Therapy - disease modifying - 28 Long-term treatment monitoring
Background: Increasingly, high efficacy infusion and oral disease modifying therapies (DMTs) possess extensive monitoring requirements during both treatment initiation and throughout the course of therapy.
Objective: To assess perceptions of the burden of monitoring requirements for multiple sclerosis (MS) treatments among healthcare professionals (HCPs) in both the 5EU (UK/Germany/France/Italy/Spain) and the United States.
Methods: The Ipsos Healthcare Global MS Therapy Monitor, a multi-centre cross-sectional survey of HCPs (mainly Neurologists; MS nurses included in UK) is run on a bi-annual basis in 5EU and US since 1997 to collect de-identified perceptions and barriers to use of DMTs. HCPs are recruited from a large panel to be geographically representative within respective countries. HCP perceptions from Q4 (September through December) in 2013, 2014, 2015, and 2016 were analysed.
Results: 270 HCPs in 5EU (2013: N=265, 2014: N=275; 2015: N=269, 2016: N=275) and 100 HCPs in the US (2013: N=100, 2014: N=100; 2015: N=111, 2016: N=99) were included. 58.4% and 60.3% of HCPs in the 5EU and US, respectively, associated high efficacy DMTs (natalizumab, alemtuzumab, fingolimod, daclizumab) with initial and on-going monitoring. The strength of this perception decreased over time (68.9% and 80.5%, respectively in 2014 to 58.4% and 60.3% in 2016). Platform orals (teriflunomide, BG-12) were also frequently perceived to have monitoring requirements (46.9% and 55.6%, respectively). 11.5% (5EU) and 17.2% (US) of HCPs also perceived the monitoring of platform orals to be a barrier to prescribing; 19.8% (5EU) and 33.1% (US) perceived the monitoring of high efficacy DMTs to be a barrier. In comparison, very few HCPs in both regions considered monitoring as a barrier to use of the platform injectables (Interferon beta-1a and 1b, Glatiramer Acetate); 2.3% (5EU) and 1.4% (US).
Conclusions: HCPs in both the 5EU and US report that required monitoring programs for infusion and oral DMTs can be a significant issue in comparison to traditional injectable treatments, that can often influence prescribing decisions. Although the perceived monitoring burden is declining over time, further research into how much this monitoring burden impacts HCP prescribing and also patient experience may be beneficial to improving access to these therapies.
Disclosure: Joanna White: nothing to disclose
Simone Gabriele: nothing to disclose
Rachael Hooper: nothing to disclose
Hannah Brown: nothing to disclose
Bijal Shah-Manek: nothing to disclose
Marco DiBonaventura: nothing to disclose
Abstract: EP1688
Type: ePoster
Abstract Category: Therapy - disease modifying - 28 Long-term treatment monitoring
Background: Increasingly, high efficacy infusion and oral disease modifying therapies (DMTs) possess extensive monitoring requirements during both treatment initiation and throughout the course of therapy.
Objective: To assess perceptions of the burden of monitoring requirements for multiple sclerosis (MS) treatments among healthcare professionals (HCPs) in both the 5EU (UK/Germany/France/Italy/Spain) and the United States.
Methods: The Ipsos Healthcare Global MS Therapy Monitor, a multi-centre cross-sectional survey of HCPs (mainly Neurologists; MS nurses included in UK) is run on a bi-annual basis in 5EU and US since 1997 to collect de-identified perceptions and barriers to use of DMTs. HCPs are recruited from a large panel to be geographically representative within respective countries. HCP perceptions from Q4 (September through December) in 2013, 2014, 2015, and 2016 were analysed.
Results: 270 HCPs in 5EU (2013: N=265, 2014: N=275; 2015: N=269, 2016: N=275) and 100 HCPs in the US (2013: N=100, 2014: N=100; 2015: N=111, 2016: N=99) were included. 58.4% and 60.3% of HCPs in the 5EU and US, respectively, associated high efficacy DMTs (natalizumab, alemtuzumab, fingolimod, daclizumab) with initial and on-going monitoring. The strength of this perception decreased over time (68.9% and 80.5%, respectively in 2014 to 58.4% and 60.3% in 2016). Platform orals (teriflunomide, BG-12) were also frequently perceived to have monitoring requirements (46.9% and 55.6%, respectively). 11.5% (5EU) and 17.2% (US) of HCPs also perceived the monitoring of platform orals to be a barrier to prescribing; 19.8% (5EU) and 33.1% (US) perceived the monitoring of high efficacy DMTs to be a barrier. In comparison, very few HCPs in both regions considered monitoring as a barrier to use of the platform injectables (Interferon beta-1a and 1b, Glatiramer Acetate); 2.3% (5EU) and 1.4% (US).
Conclusions: HCPs in both the 5EU and US report that required monitoring programs for infusion and oral DMTs can be a significant issue in comparison to traditional injectable treatments, that can often influence prescribing decisions. Although the perceived monitoring burden is declining over time, further research into how much this monitoring burden impacts HCP prescribing and also patient experience may be beneficial to improving access to these therapies.
Disclosure: Joanna White: nothing to disclose
Simone Gabriele: nothing to disclose
Rachael Hooper: nothing to disclose
Hannah Brown: nothing to disclose
Bijal Shah-Manek: nothing to disclose
Marco DiBonaventura: nothing to disclose